Template:Psilocin activities
| Target | Affinity (Ki, nM) |
|---|---|
| 5-HT1A | 49–567 (Ki) 853–>3,160 (EC50) ND (Emax) |
| 5-HT1B | 31–305 |
| 5-HT1D | 19–36 |
| 5-HT1E | 44–52 |
| 5-HT1F | ND |
| 5-HT2A | 6.0–340 (Ki) 2.4–3,836 (EC50) 16–98% (Emax) |
| 5-HT2B | 4.6–410 (Ki) 2.4–>20,000 (EC50) 38–84% (Emax) |
| 5-HT2C | 10–141 (Ki) 30.3 (EC50) 95.1% (Emax) |
| 5-HT3 | >10,000 |
| 5-HT4 | ND |
| 5-HT5A | 70–84 |
| 5-HT6 | 57–72 |
| 5-HT7 | 3.5–72 |
| α1A–α1B | >10,000 |
| α2A | 1,379–2,044 |
| α2B | 1,271–1,894 |
| α2C | 4,404 |
| β1–β2 | >10,000 |
| D1 | 20–>14,000 |
| D2 | 3,700–>10,000 |
| D3 | 101–8,900 |
| D4 | >10,000 |
| D5 | >10,000 |
| H1 | 1,600–>10,000 |
| H2–H4 | >10,000 |
| M1–M5 | >10,000 |
| σ1 | >10,000 |
| σ2 | >10,000 |
| I2 | 792 |
| TAAR1 | 1,400 (Ki) (rat) 17,000 (Ki) (mouse) 920–2,700 (EC50) (rodent) >30,000 (EC50) (human) |
| SERT | 3,800–>10,000 (Ki) 662–3,900 (IC50) 561 (EC50) 54% (Emax) |
| NET | 13,000 (Ki) 14,000 (IC50) >10,000 (EC50) |
| DAT | 6,000–>30,000 (Ki) >100,000 (IC50) >10,000 (EC50) |
| Notes: The smaller the value, the more avidly psilocin interacts with the site. Sources: [1][2][3][4][5][6][7][8][9] | |
Template documentationSee also
References
- ^ Liu T. "BindingDB BDBM50081701 3-[2-(dimethylamino)ethyl]-1H-indol-4-ol::4-hydroxy-N,N-dimethyltryptamine::CHEMBL65547::N,N-dimethyl-4-hydroxytryptamine::Psilocin::US11427604, Compound (I-45)::US11453689, Compound Psilocin::US11591353, Compound I-45::US11597738, Example 3::US11642336, Compound Psilocin::US20240051978, Compound Psilocin". BindingDB. Retrieved 5 September 2024.
- ^ Liu T. "BindingDB BDBM50171269 3-[2-(dimethylamino)ethyl]-1H-indol-4-yl dihydrogen phosphate::4-phosphoryloxy-N,N-dimethyltryptamine::CHEMBL194378::Indocybin::O-phosphoryl-4-hydroxy-N,N-dimethyltryptamine::Psilocybine::US11597738, Example 4::psilocin phosphate ester::psilocybin". BindingDB. Retrieved 5 September 2024.
- ^ "PDSP Database". UNC (in Zulu). Retrieved 2024-09-05.
- ^ "PDSP Database". UNC (in Zulu). Retrieved 2024-09-05.
- ^ Holze F, Singh N, Liechti ME, D'Souza DC (May 2024). "Serotonergic Psychedelics: A Comparative Review of Efficacy, Safety, Pharmacokinetics, and Binding Profile". Biol Psychiatry Cogn Neurosci Neuroimaging. 9 (5): 472–489. doi:10.1016/j.bpsc.2024.01.007. PMID 38301886.
- ^ Dodd S, Norman TR, Eyre HA, Stahl SM, Phillips A, Carvalho AF, Berk M (August 2023). "Psilocybin in neuropsychiatry: a review of its pharmacology, safety, and efficacy" (PDF). CNS Spectr. 28 (4): 416–426. doi:10.1017/S1092852922000888. PMID 35811423.
- ^ Tylš F, Páleníček T, Horáček J (March 2014). "Psilocybin - summary of knowledge and new perspectives". Eur Neuropsychopharmacol. 24 (3): 342–356. doi:10.1016/j.euroneuro.2013.12.006. PMID 24444771.
- ^ Wojtas A, Gołembiowska K (December 2023). "Molecular and Medical Aspects of Psychedelics". Int J Mol Sci. 25 (1): 241. doi:10.3390/ijms25010241. PMC 10778977. PMID 38203411.
- ^ Rickli A, Moning OD, Hoener MC, Liechti ME (August 2016). "Receptor interaction profiles of novel psychoactive tryptamines compared with classic hallucinogens" (PDF). Eur Neuropsychopharmacol. 26 (8): 1327–1337. doi:10.1016/j.euroneuro.2016.05.001. PMID 27216487.
- ^ Ray TS (February 2010). "Psychedelics and the human receptorome". PLOS ONE. 5 (2): e9019. Bibcode:2010PLoSO...5.9019R. doi:10.1371/journal.pone.0009019. PMC 2814854. PMID 20126400.
- ^ Plazas E, Faraone N (February 2023). "Indole Alkaloids from Psychoactive Mushrooms: Chemical and Pharmacological Potential as Psychotherapeutic Agents". Biomedicines. 11 (2): 461. doi:10.3390/biomedicines11020461. PMC 9953455. PMID 36830997.
- ^ US 11440879, Andrew Carry Kruegel, "Methods of treating mood disorders", published 10 February 2022, assigned to Gilgamesh Pharmaceuticals, Inc.
- ^ Rothman RB, Partilla JS, Baumann MH, Lightfoot-Siordia C, Blough BE (April 2012). "Studies of the biogenic amine transporters. 14. Identification of low-efficacy "partial" substrates for the biogenic amine transporters". The Journal of Pharmacology and Experimental Therapeutics. 341 (1): 251–262. doi:10.1124/jpet.111.188946. PMC 3364510. PMID 22271821.
- ^ Blough BE, Landavazo A, Decker AM, Partilla JS, Baumann MH, Rothman RB (October 2014). "Interaction of psychoactive tryptamines with biogenic amine transporters and serotonin receptor subtypes". Psychopharmacology (Berl). 231 (21): 4135–4144. doi:10.1007/s00213-014-3557-7. PMC 4194234. PMID 24800892.
- ^ Wsół A (December 2023). "Cardiovascular safety of psychedelic medicine: current status and future directions". Pharmacol Rep. 75 (6): 1362–1380. doi:10.1007/s43440-023-00539-4. PMC 10661823. PMID 37874530.
- ^ Chen X, Li J, Yu L, Maule F, Chang L, Gallant JA, Press DJ, Raithatha SA, Hagel JM, Facchini PJ (October 2023). "A cane toad (Rhinella marina) N-methyltransferase converts primary indolethylamines to tertiary psychedelic amines". J Biol Chem. 299 (10): 105231. doi:10.1016/j.jbc.2023.105231. PMC 10570959. PMID 37690691.
- ^ Chen X, Li J, Yu L, Dhananjaya D, Maule F, Cook S, Chang L, Gallant J, Press D, Bains JS, Raithatha S, Hagel J, Facchini P (10 March 2023), Bioproduction platform using a novel cane toad (Rhinella marina) N-methyltransferase for psychedelic-inspired drug discovery (PDF), doi:10.21203/rs.3.rs-2667175/v1, retrieved 18 March 2025
- ^ Gainetdinov RR, Hoener MC, Berry MD (July 2018). "Trace Amines and Their Receptors". Pharmacol Rev. 70 (3): 549–620. doi:10.1124/pr.117.015305. PMID 29941461.